We have a diverse pipeline designed to make a meaningful difference for patients
Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon® technologies and our aim to improve patients' lives. We have multiple prodrug therapies in development. Each candidate is unique and designed to be a best-in-class therapy.
Endocrinology Rare Diseases1
(Greater China)1
(Japan)2
(Global)3
(North America & Europe)4
(Greater China)1
(Japan)5
(North America, Europe, Oceania)6
(Greater China)1
Oncology4
1 In development in Greater China through strategic investments in VISEN Pharmaceuticals
2 Japanese riGHt Trial
3 Global foresigGHt Trial
4 North American and European PaTHway Trial
5 Japanese PaTHway Japan Trial
6 North America, Europe, and Oceania AComplisH Trial
7 transcendIT 101 Trial
8 IL-βelieγe Trial